Opus Genetics, Inc. (NASDAQ:IRD) Receives $10.69 Consensus Price Target from Analysts

Shares of Opus Genetics, Inc. (NASDAQ:IRD) have earned a consensus recommendation of “Moderate Buy” from the eighteen analysts that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, fifteen have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokers that have covered the stock in the last year is $11.9231.

A number of research analysts have weighed in on the stock. BTIG Research reaffirmed a “buy” rating and set a $12.00 price target on shares of Opus Genetics in a research report on Wednesday. Wall Street Zen raised shares of Opus Genetics from a “sell” rating to a “hold” rating in a research report on Sunday, August 16th. Oppenheimer raised their target price on shares of Opus Genetics from $10.00 to $20.00 and gave the company an “outperform” rating in a research note on Wednesday. TD Cowen started coverage on shares of Opus Genetics in a research note on Wednesday, July 29th. They issued a “buy” rating on the stock. Finally, Guggenheim began coverage on shares of Opus Genetics in a report on Thursday, June 4th. They set a “buy” rating and a $16.00 target price on the stock.

Insider Transactions at Opus Genetics

In other news, CEO George Magrath sold 9,475 shares of the stock in a transaction dated Thursday, July 23rd. The stock was sold at an average price of $2.95, for a total value of $27,951.25. Following the completion of the sale, the chief executive officer owned 1,731,869 shares in the company, valued at approximately $5,109,013.55. This trade represents a 0.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Robert E. Gagnon sold 28,000 shares of the stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $4.54, for a total transaction of $127,120.00. Following the completion of the sale, the chief financial officer directly owned 556,375 shares of the company’s stock, valued at $2,525,942.50. This trade represents a 4.79% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 57,331 shares of company stock worth $213,749. 11.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Engineers Gate Manager LP purchased a new stake in Opus Genetics during the 2nd quarter worth approximately $50,000. Occudo Quantitative Strategies LP purchased a new position in shares of Opus Genetics during the 4th quarter valued at approximately $25,000. Stoneridge Investment Partners LLC acquired a new stake in shares of Opus Genetics during the second quarter worth approximately $47,000. State of Wyoming bought a new stake in shares of Opus Genetics in the second quarter worth $65,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Opus Genetics in the second quarter worth $66,000. 14.97% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Opus Genetics

Here are the key news stories impacting Opus Genetics this week:

• Positive Sentiment: Encouraging gene-therapy results: Opus reported positive three- and six-month results from the low-dose cohort of its Phase 1/2 OPGx-BEST1 trial for inherited retinal disease. All five participants showed clinically meaningful visual-function improvement, while no serious adverse events or dose-limiting toxicities were observed. Opus Genetics Announces Positive Low Dose Cohort 1 Data
• Positive Sentiment: Path toward pivotal testing: Following an FDA Type C meeting, regulators aligned with a potential pivotal endpoint involving retinal sensitivity and patient-reported outcomes. Opus expects to complete second-cohort dosing in the fourth quarter of 2026 and potentially begin Phase 3 dosing in 2027. Management also said its cash runway extends into 2029, reducing near-term financing risk. Opus Genetics Reports Positive OPGx-BEST1 Data
• Positive Sentiment: Analyst support increased: Wedbush raised its price target to $13 from $10 and maintained an “outperform” rating. Oppenheimer raised its target to $20 from $10, while BTIG, Chardan Capital and HC Wainwright reaffirmed bullish ratings with targets ranging from $8 to $13. These targets imply substantial potential upside, although they remain dependent on clinical execution.
• Positive Sentiment: Options activity signals optimism: Traders purchased 4,820 call options, approximately 681% above typical volume, suggesting increased speculative interest in further gains.
• Neutral Sentiment: Analyst views are not unanimous: Coverage remains broadly bullish, but some analysts hold more cautious ratings, making the overall outlook supportive but mixed. Analysts’ Opinions Are Mixed on Opus Genetics
• Negative Sentiment: Insider sale: CFO Robert Gagnon sold 28,000 shares worth about $127,120 to cover tax withholding tied to equity vesting. The transaction was relatively small and attributed to taxes, but could still be viewed as a modest negative signal.

Opus Genetics Price Performance

Shares of NASDAQ:IRD opened at $6.07 on Friday. The business has a 50-day moving average of $3.86 and a two-hundred day moving average of $4.32. The firm has a market capitalization of $501.69 million, a PE ratio of -4.50 and a beta of 0.58. Opus Genetics has a 12 month low of $1.32 and a 12 month high of $7.07.

Opus Genetics (NASDAQ:IRD) last issued its earnings results on Thursday, August 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.02. The business had revenue of $0.76 million during the quarter, compared to analysts’ expectations of $2.63 million. Opus Genetics had a negative return on equity of 338.88% and a negative net margin of 1,091.82%. As a group, research analysts anticipate that Opus Genetics will post -0.99 earnings per share for the current year.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.